Survodutide (BI 456906)
Obesity
Key Facts
About Zealand Pharma
Zealand Pharma leverages its proprietary peptide platform to design and develop novel therapeutics, with a core focus on metabolic and gastrointestinal disorders. The company has achieved significant milestones, including the commercialization of V-Go® for diabetes and the advancement of a high-potential pipeline led by survodutide, a GLP-1/glucagon dual agonist with blockbuster potential in obesity. Strategic partnerships with Boehringer Ingelheim and a strong financial position underpin its strategy to become a leader in peptide therapeutics.
View full company profileAbout Zealand Pharma
Zealand Pharma leverages its proprietary peptide platform to design and develop novel therapeutics, with a core focus on metabolic and gastrointestinal disorders. The company has achieved significant milestones, including the commercialization of V-Go® for diabetes and the advancement of a high-potential pipeline led by survodutide, a GLP-1/glucagon dual agonist with blockbuster potential in obesity. Strategic partnerships with Boehringer Ingelheim and a strong financial position underpin its strategy to become a leader in peptide therapeutics.
View full company profileTherapeutic Areas
Other Obesity Drugs
| Drug | Company | Phase |
|---|---|---|
| Tirzepatide (Zepbound) | Eli Lilly | Approved |
| APJ Program | BioAge Labs | Preclinical |
| Wegovy HD (semaglutide 7.2mg) | Novo Nordisk | Approved |
| Amylin analogue (subcutaneous) | Novo Nordisk | Phase 1 |
| GLP1-GIP-Amylin tri-agonist | Novo Nordisk | Phase 2 |
| VK2735 (subcutaneous) | Viking Therapeutics | Phase 3 |
| VK2735 (oral) | Viking Therapeutics | Phase 1/2 |
| GSBR-1290 | Structure Therapeutics | Phase 2 |
| LTSE-2578 | Structure Therapeutics | Preclinical |
| ZP8396 | Zealand Pharma | Preclinical/Phase 1 |
| Pemvidutide (ALT-801) | Altimmune | Phase 2 |
| PL7737 | Palatin Technologies | Preclinical |